1. **PRODUCT NAME**

COSUDEX 50 mg tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film coated tablet contains 50 mg bicalutamide.

COSUDEX 50 mg is a white film-coated tablet impressed with CDX50 on one side and a logo on the other.

3. **PHARMACEUTICAL FORM**

Film coated tablet.

4. **CLINICAL PARTICULARS**

4.1 **THERAPEUTIC INDICATIONS**

Treatment of advanced prostate cancer in combination with GnRH luteinizing-hormone releasing hormone (LHRH) agonist therapy or surgical castration.

Prevention of disease flare associated with the use of LHRH agonists.

4.2 **DOSE AND METHOD OF ADMINISTRATION**

**AS COMBINATION THERAPY IN ADULT MALES INCLUDING THE ELDERLY**

One tablet (50 mg) once a day.

Treatment with COSUDEX should be started at the same time as treatment with a GnRH (LHRH) agonist or surgical castration.

**CHILDREN**

COSUDEX is contraindicated in children.

**USE IN ADULT MALES WITH RENAL IMPAIRMENT**

No dosage adjustment is necessary for patients with renal impairment.

**USE IN ADULT MALES WITH HEPATIC IMPAIRMENT**

No dosage adjustment is necessary for patients with mild hepatic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment (see section 4.4).

4.3 **CONTRAINDICATIONS**

COSUDEX is contraindicated in females and children.

COSUDEX must not be given to any patient who has shown a hypersensitivity reaction to the active substance or to any of the excipients.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Bicalutamide is extensively metabolised in the liver. Data suggest that its elimination may be slower in subjects with severe hepatic impairment and this could lead to increased accumulation of bicalutamide. Therefore, COSUDEX should be used with caution in patients with moderate to severe hepatic impairment.

Periodic liver function testing should be considered due to the possibility of hepatic changes.

Severe hepatic changes and hepatic failure have been observed rarely with COSUDEX, and fatal outcomes have been reported (see section 4.8). COSUDEX therapy should be discontinued if changes are severe.

A reduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as diabetes or loss of glycaemic control in those with pre-existing diabetes. Consideration should therefore be given to monitoring blood glucose in patients receiving COSUDEX in combination with LHRH agonists.

Androgen deprivation therapy may prolong the QT interval, although a causal association has not been established with COSUDEX. In patients with a history of or who have risk factors for QT prolongation and in patients receiving concomitant medicinal products that may prolong the QT interval (see section 4.5) physicians should assess the benefit risk ratio including the potential for Torsade de Pointes prior to initiating COSUDEX.

Antiandrogen therapy may cause morphological changes in spermatozoa. Although the effect of bicalutamide on sperm morphology has not been evaluated and no such changes have been reported for patients who received COSUDEX, patients and/or their partners should use adequate contraception methods during and for 130 days after COSUDEX therapy.

Potentiation of coumarin anticoagulant effects have been reported in patients receiving concomitant COSUDEX therapy, which may result in increased Prothrombin Time (PT) and International Normalised Ratio (INR). Some cases have been associated with risk of bleeding. Close monitoring of PT/INR is advised and anticoagulant dose adjustment should be considered (see sections 4.5 and 4.8).

4.5 INTERACTION WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTION

There is no evidence of any pharmacodynamic or pharmacokinetic interactions between COSUDEX and GnRH analogues.

In vitro studies have shown that R-bicalutamide is an inhibitor of CYP3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.

Although in vitro studies have suggested the potential for COSUDEX to inhibit cytochrome 3A4, a number of clinical studies show the magnitude of any inhibition is unlikely to be of clinical significance.

In vitro studies have shown that bicalutamide can displace the coumarin anticoagulant, warfarin, from its protein binding sites. There have been reports of increased effect of warfarin and other coumarin anticoagulants when co-administered with COSUDEX. It is
therefore recommended that if COSUDEX is administered in patients who are concomitantly receiving coumarin anticoagulants, PT/INR should be closely monitored and adjustments of anticoagulant dose considered (see sections 4.4 and 4.8).

Although there is no evidence of any pharmacodynamic or pharmacokinetic interactions between COSUDEX 50 mg and LHRH agonists at steady state, COSUDEX 50 mg may prevent the harmful clinical consequences of flare associated with the start of LHRH agonist therapy.

Since androgen deprivation treatment may prolong the QT interval, the concomitant use of COSUDEX with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de Pointes should be carefully evaluated (see section 4.4).

4.6 FERTILITY, PREGNANCY AND LACTATION

Pregnancy COSUDEX is contraindicated in females and must not be given to pregnant women.

Breast-feeding
COSUDEX is contraindicated during breast-feeding.

Fertility
Reversible impairment of male fertility has been observed in animal studies (see section 5.3). A period of subfertility or infertility should be assumed in man.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

During treatment with COSUDEX, somnolence has been reported and those patients who experience this symptom should observe caution when driving or using machines.

4.8 UNDESIRABLE EFFECTS

Unless specified, the following frequency categories were assigned based on the incidence of the adverse event in the 50 mg COSUDEX plus LHRH analogue arm of the pivotal LHRH combination study.

<table>
<thead>
<tr>
<th>Frequency</th>
<th>System Organ Class</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common (≥10%)</td>
<td>Blood and lymphatic</td>
<td>Anaemia</td>
</tr>
<tr>
<td></td>
<td>Nervous system disorders</td>
<td>Dizziness</td>
</tr>
<tr>
<td></td>
<td>Vascular disorders</td>
<td>Hot flush</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal disorders</td>
<td>Abdominal pain, constipation, nausea</td>
</tr>
<tr>
<td></td>
<td>Renal and urinary disorders</td>
<td>Haematuria</td>
</tr>
<tr>
<td></td>
<td>Reproductive system and breast disorders</td>
<td>Gynaecomastia and breast tendernessa</td>
</tr>
<tr>
<td></td>
<td>General disorders and administration site conditions</td>
<td>Asthenia, oedema</td>
</tr>
<tr>
<td>Frequency</td>
<td>System Organ Class</td>
<td>Event</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Common (≥1% and &lt;10%)</td>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td></td>
<td>Psychiatric disorders</td>
<td>Decreased libido, depression</td>
</tr>
<tr>
<td></td>
<td>Nervous system disorders</td>
<td>Somnolence</td>
</tr>
<tr>
<td></td>
<td>Cardiac disorders</td>
<td>Myocardial infarction (fatal outcomes have been reported)(^a), Cardiac failure(^a)</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal disorders</td>
<td>Dyspepsia, flatulence,</td>
</tr>
<tr>
<td></td>
<td>Hepatobiliary disorders</td>
<td>Hepatotoxicity, jaundice, hypertransaminasaemia(^b)</td>
</tr>
<tr>
<td></td>
<td>Skin and subcutaneous tissue disorders</td>
<td>Alopecia, hirsutism/ hair regrowth, rash, dry skin, pruritus</td>
</tr>
<tr>
<td></td>
<td>Reproductive system and breast disorders</td>
<td>Erectile dysfunction</td>
</tr>
<tr>
<td></td>
<td>General disorders and administration site conditions</td>
<td>Chest pain</td>
</tr>
<tr>
<td></td>
<td>Investigations</td>
<td>Weight increased</td>
</tr>
<tr>
<td>Uncommon (≥0.1% and &lt;1%)</td>
<td>Immune system disorders</td>
<td>Hypersensitivity, angioedema, and urticaria</td>
</tr>
<tr>
<td></td>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Interstitial lung disease(^c). Fatal outcomes have been reported.</td>
</tr>
<tr>
<td>Rare (≥0.01% and &lt;0.1%)</td>
<td>Hepatobiliary disorders</td>
<td>Hepatic failure(^d). Fatal outcomes have been reported.</td>
</tr>
<tr>
<td></td>
<td>Skin and subcutaneous tissue disorders</td>
<td>Photosensitivity reaction</td>
</tr>
</tbody>
</table>

\(^a\) May be reduced by concomitant castration.

\(^b\) Hepatic changes are rarely severe and were frequently transient, resolving or improving with continued therapy or following cessation of therapy.

\(^c\) Listed as an adverse drug reaction following review of post-marketed data. Frequency has been determined from the incidence of reported adverse events of interstitial pneumonia in the randomised treatment period of the 150 mg EPC studies.

\(^d\) Listed as an adverse drug reaction following review of post-marketed data. Frequency has been determined from the incidence of reported adverse events of hepatic failure in patients receiving treatment in the open-label COSUDEX arm of the 150 mg EPC studies.

\(^e\) Observed in a pharmacoepidemiology study of LHRH agonists and anti-androgens used in the treatment of prostate cancer. The risk appeared to be increased when COSUDEX 50 mg was used in combination with LHRH agonists.

Increased PT/INR: Accounts of coumarin anticoagulants interacting with COSUDEX have been reported in post marketing surveillance (see sections 4.4. and 4.5).

**REPORTING OF SUSPECTED ADVERSE REACTIONS**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare
professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/.

4.9 OVERDOSE
There is no human experience of overdosage. There is no specific antidote; treatment should be symptomatic. Dialysis may not be helpful, since COSUDEX is highly protein bound and is not recovered unchanged in the urine. General supportive care, including frequent monitoring of vital signs, is indicated.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764 766).

5. PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES
COSUDEX is a non-steroidal anti-androgen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Clinically, discontinuation of COSUDEX can result in antiandrogen withdrawal syndrome in a subset of patients.

COSUDEX is a racemate with its antiandrogenic activity being almost exclusively in the R-enantiomer.

5.2 PHARMACOKINETIC PROPERTIES
COSUDEX is well absorbed following oral administration. There is no evidence of any clinically relevant effect of food on bioavailability.

The (S)-enantiomer is rapidly cleared relative to the (R)-enantiomer, the latter having a plasma elimination half-life of about 1 week.

On daily administration of COSUDEX, the (R)-enantiomer accumulates about 10-fold in plasma as a consequence of its long half-life.

Steady state plasma concentrations of the (R)-enantiomer of approximately 9 µg/mL are observed during daily administration of 50 mg doses of COSUDEX. At steady state the predominantly active (R)-enantiomer accounts for 99% of the total circulating enantiomers.

The pharmacokinetics of the (R)-enantiomer are unaffected by age, renal impairment or mild to moderate hepatic impairment. There is evidence that for subjects with severe hepatic impairment, the (R)-enantiomer is more slowly eliminated from plasma.

COSUDEX is highly protein bound (racemate 96%, R-bicalutamide 99.6%) and extensively metabolised (oxidation and glucuronidation); its metabolites are eliminated via the kidneys and bile in approximately equal proportions.

In a clinical study the mean concentration of R-bicalutamide in semen of men receiving Cosudex 150 mg was 4.9 µg/mL. The amount of bicalutamide potentially delivered to a female partner during intercourse is low and equates to approximately 0.3 µg/kg. This is below that required to induce changes in offspring of laboratory animals.
5.3 PRECLINICAL SAFETY DATA

Bicalutamide is a potent antiandrogen and a mixed function oxidase enzyme inducer in animals. Target organ changes, including tumour induction and minor clinical pathology changes, are related to these activities. Enzyme induction and minor cardiac changes seen in dogs have not been observed in man. Atrophy of seminiferous tubules of the testes is a predicted class effect with anti-androgens and has been observed for all species examined. Reversal of testicular atrophy occurred 4 months after the completion of dosing in a 6-month rat study (at doses of approximately 1.5 or 0.6 times human therapeutic concentrations at the recommended dose of 50 mg or 150 mg, respectively). No recovery was observed at 24 weeks after the completion of dosing in a 12-month rat study (at doses of approximately 2 or 0.9 times human concentrations at the recommended human dose of 50 mg or 150 mg, respectively). Following 12-months of repeated dosing in dogs (at doses of approximately 7 or 3 times human therapeutic concentrations at the recommended human dose of 50 mg or 150 mg, respectively), the incidence of testicular atrophy was the same in dosed and control dogs after a 6 month recovery period. In a fertility study (at doses of approximately 1.5 or 0.6 times human therapeutic concentrations at the recommended human dose of 50 mg or 150 mg, respectively), male rats had an increased time to successful mating immediately after 11 weeks of dosing; reversal was observed after 7 weeks off-dose.

6. PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS
- Lactose Monohydrate
- Sodium Starch Glycollate
- Povidone
- Magnesium Stearate
- Hypermellose
- Macrogol 300
- Titanium Dioxide

6.2 INCOMPATIBILITIES
Not applicable

6.3 SHELF LIFE
5 years

6.4 SPECIAL PRECAUTIONS FOR STORAGE
Store below 30°C.

6.5 NATURE AND CONTENTS OF CONTAINER
Blister pack 28 tablets.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING
Return unused and expired medicines to your local pharmacy for disposal.

7. MEDICINE SCHEDULE
Prescription Medicine.
8. **SPONSOR**
AstraZeneca Limited
P299 Private Bag 92175
Auckland 1142
Telephone: (09) 306 5650

9. **DATE OF FIRST APPROVAL**
11 January 2001

10. **DATE OF REVISION OF TEXT**
31 July 2017

CDS 200217

© This data sheet is copyrighted to AstraZeneca Limited and may be reproduced but not altered in any way.

**SUMMARY TABLE OF CHANGES**

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4, 4.5 &amp; 4.8</td>
<td>SPC style format changes only. New information added regarding potentiation of coumarin when taken with Cosudex.</td>
</tr>
<tr>
<td>4.6</td>
<td>Subheadings added. Information added regarding male fertility</td>
</tr>
<tr>
<td>5.3</td>
<td>Information added corresponding with new text in 4.6 regarding male fertility.</td>
</tr>
</tbody>
</table>